Get the Stockscreener App
1.67
8.49%
-0.155
Pre-market:
2.20
0.53
+31.74%
Lakewood Amedex Biotherapeutics Inc stock is traded at $1.67, with a volume of 174.16K.
It is down -8.49% in the last 24 hours and down -27.07% over the past month.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
See More
Previous Close:
$1.825
Open:
$1.85
24h Volume:
174.16K
Relative Volume:
0.10
Market Cap:
$3.96M
Revenue:
-
Net Income/Loss:
$-4.23M
P/E Ratio:
-0.1898
EPS:
-8.8
Net Cash Flow:
$-1.89M
1W Performance:
-16.08%
1M Performance:
-27.07%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.63
$1.85
1-Week Range:
$1.63
$2.10
52-Week Range:
$0.366
$9.40
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Company Profile
Name
Lakewood Amedex Biotherapeutics Inc
Sector
Industry
Phone
(941) 225-2515
Address
8031 COOPER CREEK BLVD., UNIVERSITY PARK
Compare LABT vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LABT
Lakewood Amedex Biotherapeutics Inc
|
1.67 | 3.96M | 0 | -4.23M | -1.89M | -8.80 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Latest News
Is Lakewood-Amedex Biotherapeutics Inc. (LABT) Rewriting the Penny Stocks Playbook? - Kalkine Media
Lakewood-Amedex Biotherapeutics Inc. SEC Filing (Sep 25, 2026) - Stock Titan
Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial - AOL.ca
Lakewood-Amedex Biotherapeutics (LABT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Lakewood-Amedex doses first patient in Nu-3 diabetic ulcer trial - Investing.com Canada
How Is Lakewood-Amedex (NASDAQ:LABT) Preparing Its Nu-3 Program for Midstage Testing? - Kalkine Media
First patient dosed in Phase 2a trial of Nu-3 a... - Pluang
The first patient has received a germ-fighting gel being tested for infected diabetic foot ulcers. - Stock Titan
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 - The Columbus Dispatch
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead By Investing.com - Investing.com Nigeria
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead - Investing.com India
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 - PR Newswire
IPO Databook: Lakewood-Amedex Biotherapeutics (LABT US)Sep 2026 - Smartkarma
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers - TechFinancials
Lakewood-Amedex Announces IRB Approval to Initiate Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers - The National Law Review
Lakewood-Amedex (NASDAQ: LABT) faces shareholder stock resale that brings it no cash - Stock Titan
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
Lakewood-Amedex Biotherapeutics Announces IRB Approval - openPR.com
Lakewood-Amedex receives approval to start phase 2a trial - Investing.com
Lakewood-Amedex receives approval to start phase 2a trial By Investing.com - Investing.com Canada
A new gel for infected diabetic foot ulcers is ready for a clinical trial - Stock Titan
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - Kalkine
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - openPR.com
Lakewood-Amedex CEO to present new antimicrobia... - Pluang
Biotech Pre-Market Movers: BIAF, LABT, ALMS, PASW Swing Big - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Trending Stocks Today | SONO Group Soars 81.34% Post-Market - Moomoo
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - markets.businessinsider.com
Lakewood-Amedex Biotherapeutics (LABT) Stock Trends and Sentiment 2026 $LABT - MarketBeat
Lakewood-Amedex Biotherapeutics (LABT) investor WFI Equity discloses 8.8% ownership stake - Stock Titan
Lakewood-Amedex raises $7.5M Series C, lists on Nasdaq and clears $1.5M debt - Dealroom
Lakewood-Amedex Raises $7.5M and Lists on NASDAQ, Shedding $1.5M Debt - Minichart
LABT: Q2 net loss rose sharply on higher R&D and G&A costs; liquidity improved after Series C financing - TradingView
Lakewood-Amedex Biotherapeutics Inc. Q2 2026: Revenue $0 Net loss $(3.90M), EPS $(2.75) — 10-Q Summary - TradingView
Lakewood-Amedex (NASDAQ: LABT) raises $7.5M, expands cash yet flags going concern - Stock Titan
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia
Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget
Lakewood-Amedex (NASDAQ: LABT) seeks 100M share authorization and reverse split power - Stock Titan
Lindesfarne LLC reports 8.582% LABT stake in Lakewood-Amedex Biotherapeutics (LABT) filing - Stock Titan
Lakewood-Amedex Biotherapeutics (LABT) Earnings Date and Reports 2026 $LABT - MarketBeat
Lakewood-Amedex Biotherapeutics (LABT) asks investors to approve major share and reverse split powers - Stock Titan
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):